Are Physicians “Easy Marks”? Quantifying the Effects of Detailing and Sampling on New Prescriptions

References

• Anderson T. W., Hsiao Cheng. Formulation and estimation of dynamic models using panel data. J. Econometrics (1982) 18(1):47–82Crossref, Google Scholar
• Arellano Manuel. Panel Data Econometrics (2003) (Oxford University Press, Inc., New York) Crossref, Google Scholar
• Arellano Manuel, Bond Stephen. Some tests of specification for panel data: Monte Carlo evidence and an application to employment equations. Rev. Econom. Stud. (1991) 58(194):277–297Crossref, Google Scholar
• Avorn Jerry, Chen Milton, Hartley Robert. Commercial versus scientific sources of influence on the prescribing behavior of physicians. Amer. J. Medicine (1982) 73(July):4–8Crossref, Google Scholar
• Azoulay Pierre. Do pharmaceutical sales respond to scientific evidence? J. Econom. Management Strategy (2002) 11(4):551–594Crossref, Google Scholar
• Berndt Ernst R., Pindyck Robert S., Azoulay Pierre. Consumption externalities and diffusion in pharmaceutical markets: Antiulcer drugs. J. Indust. Econom. (2003) 51(2):243–270Crossref, Google Scholar
• Campbell Margaret C., Kirmani Amna. Consumers' use of persuasion knowledge: The effects of accessibility and cognitive capacity on perceptions of an influence agent. J. Consumer Res. (2000) 27(June):69–83Crossref, Google Scholar
• Chren Mery-Margaret, Landefeld C. Seth. Physicians' behavior and their interactions with drug companies: A controlled study of physicians who requested additions to a hospital drug formulary. J. Amer. Medical Assoc. (1994) 271(9):684–689Crossref, Google Scholar
• Connelly Donald P., Rich Eugene C., Curley S. P., Kelley J. T. Knowledge resource preferences of family physicians. J. Family Practice (1990) 30(3):353–359Google Scholar
• Dholakia Ruby Roy, Sternthal Brian. Highly credible sources: Persuasive facilitators or persuasive liabilities? J. Consumer Res. (1977) 3(March):223–232Crossref, Google Scholar
• Eagley Alice H., Chaiken Shelly. An attribution analysis of the effect of communicator characteristics on the opinion change: The case of communicator attractiveness. J. Personality Soc. Psych. (1975) 32(July):136–144Crossref, Google Scholar
• Elling Martin E., Fogle Holly J., McKhann Charles S., Simon Chris. Making more of pharma's sales force. McKinsey Quart. (2002) 3:86–95Google Scholar
• Friestad Marian, Wright Peter. The persuasion knowledge model: How people cope with persuasion attempts. J. Consumer Res. (1994) 21(June):1–31Crossref, Google Scholar
• Gold Russell. States battling high drug costs appeal to doctors. Wall Street Journal (2001) August 22):B1–B8Google Scholar
• Gonul Fusun F., Carter Franklin, Petrova Elina, Srinivasan Kanan. Promotion of prescription drugs and its impact of physician choice behavior. J. Marketing (2001) 65(3):79–90Crossref, Google Scholar
• Hausman Jerry A. Specification tests in econometrics. Econometrica (1978) 46:1251–1272Crossref, Google Scholar
• Hensley S. Sorry Doc, no dinners-to-go—Drug sales reps begin building a new marketing playbook. Wall Street Journal (2002) April 23):D4Google Scholar
• IMS Health IMS review: Steady but not stellar. Medical Marketing Media (2003) 38(May):50–63Google Scholar
• Krinsky Itzhak, Robb A. Leslie. On approximating the statistical properties of elasticities. Rev. Econom. Statist. (1986) 68(3):715–719Crossref, Google Scholar
• Lichstein Peter R., Turner Robert C., O'Brien Kevin. Impact of pharmaceutical company representatives on internal medicine residency programs: A survey of residency program directors. Arch. Internal Medicine (1992) 152(5):1009–1013Crossref, Google Scholar
• McKinley W. Paul, Schiedermayer David L., Lurie Nicole, Simpson Deborah E., Goldman Jesse L., Rich Eugene C. Attitudes of internal medicine faculty and residents toward professional interactions with pharmaceutical sales representatives. J. Amer. Medical Assoc. (1990) 264(13):1693–1697Crossref, Google Scholar
• Narayanan Sridhar, Desiraju Ramarao, Chintagunta Pradeep K.ROI implications for pharmaceutical promotional expenditures: The case of second-generations antihistamines (2003) . Working paper, University of Chicago, Chicago, ILGoogle Scholar
• Parsons Leonard Jon, Abeele Piet Vanden. Analysis of sales call effectiveness. J. Marketing Res. (1981) 18(February):107–113Crossref, Google Scholar
• Pear Robert. Congress weighs drug comparisons. New York Times (2003) August 24):1Google Scholar
• Peay Marilyn Y., Peay Edmund R. Patterns of preference for information sources in the adoption of a new drugs by specialists. Social Sci. Medicine (1990) 31(4):467–476Crossref, Google Scholar
• Powers Roxann. Time with drug representatives affects prescribing. 21st Annual Meeting of the Society of General Internal Medicine (1998) (Chicago, IL)Google Scholar
• Rizzo John A. Advertising and competition in the ethical pharmaceutical industry: The case of antihypertensive drugs. J. Law Econom. (1999) 42(April):89–116Crossref, Google Scholar
• Washington Post U.S. issues warning to drug industry. (2002) October 2):E1Google Scholar
• Wickens Michael R. A note on the use of proxy variables. Econometrica (1972) 40(4):759–761Crossref, Google Scholar
• Wotruba Thomas R. Comment on “Analysis of sales force effectiveness.”. J. Marketing Res. (1982) 19(November):595–596Crossref, Google Scholar
• Zigler Michael G., Lew Pauline, Singer Brian C. The accuracy of drug information from pharmaceutical sales representatives. J. Amer. Medical Assoc. (1995) 273(16):1296–1298Crossref, Google Scholar